Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA14 | Q9ULX7 | 3/20 | 0.41 |
| ▸ | CA12 | O43570 | 2/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.37 |
| ▸ | CA7 | P43166 | 1/20 | 0.33 |
| ▸ | CA9 | Q16790 | 1/20 | 0.33 |
| ▸ | TSHR | P16473 | 1/20 | 0.31 |
| ▸ | TAS1R3 | Q7RTX0 | 1/20 | 0.30 |
| ▸ | TAS1R1 | Q7RTX1 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8610882 | 0.84 | CA14 (0.52) | CA14CA12SMN1; SMN2CA7CA9 | |
| SCHEMBL3201070 | 0.84 | CA14 (0.52) | CA14CA12SMN1; SMN2CA7CA9 | |
| SCHEMBL8017536 | 0.78 | POLB (0.41) | TAS1R3TAS1R1 | |
| SCHEMBL15904132 | 0.77 | TP53 (0.39) | — | |
| SCHEMBL23573085 | 0.76 | — | — | |
| SCHEMBL26360906 | 0.76 | CA14 (0.42) | CA14CA12SMN1; SMN2CA7CA9 | |
| SCHEMBL23758442 | 0.76 | CA14 (0.42) | CA14CA12SMN1; SMN2CA7CA9 | |
| SCHEMBL28868142 | 0.76 | CA14 (0.42) | CA14CA12SMN1; SMN2CA7CA9 | |
| SCHEMBL24556376 | 0.75 | CA14 (0.45) | CA14CA12SMN1; SMN2CA7CA9 | |
| SCHEMBL24445693 | 0.75 | CA14 (0.45) | CA14CA12SMN1; SMN2CA7CA9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100029724-A1 | SCREENING METHOD | TAKEDA PHARMACEUTICAL COMPANY LIMITED | 2010-02-04 | — | — | US | disclosed |
| EP-2039779-A1 | SCREENING METHOD | Takeda Pharmaceutical Company Limited (JP) | 2009-03-25 | — | — | EP | disclosed |
| US-20080287438-A1 | Agent for preventing or treating neuropathy | MOMOSE YU | 2008-11-20 | — | — | US | disclosed |
| US-7423159-B2 | Agent for preventing or treating neuropathy | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2008-09-09 | — | — | US | disclosed |
| US-7183276-B2 | Azole compounds | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2007-02-27 | — | — | US | disclosed |
| US-20060004069-A1 | Agent for preventing or treating neuropathy | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2006-01-05 | — | — | US | disclosed |
| US-20050090534-A1 | Azole compounds | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2005-04-28 | — | — | US | disclosed |
| EP-1486490-A1 | AZOLE COMPOUNDS | Takeda Chemical Industries, Ltd. (JP) | 2004-12-15 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050090534-A1 | Azole compounds | AHR, NR0B2, NR2C2 | CA14 2335/4885CA12 2146/4885SMN1; SMN2 584/4885 |
| US-20100029724-A1 | SCREENING METHOD | NR2C2, NCOR2, NCOA2 | CA14 1529/4885CA12 723/4885SMN1; SMN2 620/4885 |
| US-20060004069-A1 | Agent for preventing or treating neuropathy | NR2C2, NR0B2, NR2E1 | CA14 4354/4885CA12 3141/4885SMN1; SMN2 75/4885 |
| US-20080287438-A1 | Agent for preventing or treating neuropathy | NR2C2, NR0B2, NR2E1 | CA14 4354/4885CA12 3141/4885SMN1; SMN2 75/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.